User profiles for J. Diebold

Joachim Diebold

Professor für Pathologie, Luzerner Kantonsspital
Verified email at luks.ch
Cited by 14599

[HTML][HTML] Lymphoma classification–from controversy to consensus: the REAL and WHO Classification of lymphoid neoplasms

NL Harris, ES Jaffe, J Diebold, G Flandrin… - Annals of oncology, 2000 - Elsevier
Background: Controversy in lymphoma classification dates back to the first attempts to formulate
such classifications. Over the years, much of this controversy arose from the assumption …

A review of the chemical and physical mechanisms of the storage stability of fast pyrolysis bio-oils

JP Diebold - 1999 - osti.gov
Understanding the fundamental chemical and physical aging mechanisms is necessary to
learn how to produce a bio-oil that is more stable during shipping and storage. This review …

[HTML][HTML] Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project

AM Perry, J Diebold, BN Nathwani… - …, 2016 - ncbi.nlm.nih.gov
The distribution of non-Hodgkin lymphoma subtypes varies around the world, but a large
systematic comparative study has never been done. In this study, we evaluated the clinical …

The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting …

NL Harris, ES Jaffe, J Diebold, G Flandrin… - Annals of …, 1999 - Elsevier
Introduction Since 1995, the European Association of Pathologists (EAHP) and the Society
for Hematopathology (SH) have been developing a new World Health Organization (WHO) …

[HTML][HTML] Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

…, TL Ng, V Gounant, S Popat, J Diebold, J Sabari… - Annals of …, 2019 - Elsevier
Background Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to
treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across …

Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation.

…, PL Crotty, J McGrath, D Berrebi, J Diebold… - The American journal …, 1998 - ncbi.nlm.nih.gov
Inhibitors of programmed cell death (apoptosis) may regulate tissue differentiation and
aberrantly promote cell survival in neoplasia. A novel apoptosis inhibitor of the IAP gene family, …

From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression

…, M Kaufmann, J Diebold… - Proceedings of the …, 2003 - National Acad Sciences
According to the present view, metastasis marks the end in a sequence of genomic changes
underlying the progression of an epithelial cell to a lethal cancer. Here, we aimed to find out …

[PDF][PDF] Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

…, E Dansin, C Chouaid, M Wislez, J Diebold… - Journal of clinical …, 2013 - cancer.net
… Cortot, Fabrice Barlesi, Michéle Beau-Faller, Benjamin Besse, Thierry Urban, Denis Moro-Sibilot,
Eric Dansin, Christos Chouaid, Marie Wislez, Joachim Diebold, Julie D. Milia, Oliver …

Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer

…, T Knyazeva, H Körner, P Knyazev, J Diebold… - Cell cycle, 2008 - Taylor & Francis
Recently, we and others identified the microRNA miR-34a as a target of the tumor suppressor
gene product p53. Ectopic miR-34a induces a G1 cell cycle arrest, senescence and …

Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas

…, F Berger, R Bouhabdallah, J Diebold - Blood, The Journal …, 1998 - ashpublications.org
Peripheral T-cell lymphomas (PTCL) have been generally reported to have a worse prognosis
than B-cell lymphomas (BCL). Because of their heterogeneity and scarcity, the outcomes …